| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $2,722,037 | 9 | 90 |
Sells | $8,330,080 | 1 | 10 |
| SIEGALL CLAY B | President and CEO | 4 | $2.25M | 0 | $0 | $2.25M |
| Tsai Philip | Chief Technology Officer | 2 | $308,466 | 0 | $0 | $308,466 |
| BIENAIME JEAN JACQUES | director | 3 | $165,054 | 0 | $0 | $165,054 |
| Barchas Isaac | director | 0 | $0 | 1 | $8.33M | $-8.33M |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Over the last 12 months, insiders at Immunome, Inc. have bought $2.72M and sold $8.33M worth of Immunome, Inc. stock.
On average, over the past 5 years, insiders at Immunome, Inc. have bought $2.73M and sold $4.3M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SIEGALL CLAY B (President and CEO) — $2.25M. Tsai Philip (Chief Technology Officer) — $308,466. BIENAIME JEAN JACQUES (director) — $165,054.
The last purchase of 4,729 shares for transaction amount of $100,018 was made by SIEGALL CLAY B (President and CEO) on 2025‑12‑30.
| 2025-12-30 | SIEGALL CLAY B | President and CEO | 4,729 0.0051% | $21.15 | $100,018 | +5.85% | ||
| 2025-12-22 | Sale | Barchas Isaac | director | 383,200 0.4123% | $21.74 | $8.33M | +1.09% | |
| 2025-12-19 | SIEGALL CLAY B | President and CEO | 7,278 0.0076% | $20.48 | $149,053 | +3.59% | ||
| 2025-12-19 | Tsai Philip | Chief Technical Officer | 10,000 0.0104% | $20.49 | $204,900 | +3.59% | ||
| 2025-12-18 | SIEGALL CLAY B | President and CEO | 46,511 0.0547% | $21.50 | $999,987 | +11.20% | ||
| 2025-06-03 | BIENAIME JEAN JACQUES | director | 5,000 0.0058% | $9.38 | $46,900 | +68.30% | ||
| 2025-03-26 | SIEGALL CLAY B | President and CEO | 137,100 0.1621% | $7.29 | $999,459 | +53.03% | ||
| 2025-03-25 | BIENAIME JEAN JACQUES | director | 7,800 0.01% | $7.78 | $60,684 | +56.04% | ||
| 2025-03-24 | Tsai Philip | Chief Technology Officer | 12,300 0.0146% | $8.42 | $103,566 | +33.01% | ||
| 2025-03-24 | BIENAIME JEAN JACQUES | director | 7,000 0.0081% | $8.21 | $57,470 | +33.01% | ||
| 2025-01-31 | SIEGALL CLAY B | President and CEO | 150,000 0.1772% | $7.75 | $1.16M | -9.79% | ||
| 2024-11-22 | SIEGALL CLAY B | President and CEO | 33,943 0.0543% | $9.78 | $331,918 | +0.81% | ||
| 2024-11-21 | SIEGALL CLAY B | President and CEO | 66,057 0.1059% | $9.54 | $630,263 | +5.10% | ||
| 2024-11-21 | Tsai Philip | Chief Technology Officer | 21,000 0.0333% | $9.43 | $198,030 | +5.10% | ||
| 2024-11-21 | Lechleider Robert | Chief Medical Officer | 15,805 0.0252% | $9.48 | $149,800 | +5.10% | ||
| 2024-09-19 | Sale | Rosett Max | Chief Financial Officer | 14,380 0.0251% | $16.01 | $230,224 | -35.55% | |
| 2024-08-16 | BIENAIME JEAN JACQUES | director | 7,000 0.0128% | $13.94 | $97,608 | -24.83% | ||
| 2024-08-15 | Sale | Higgins Jack | Chief Scientific Officer | 3,524 0.0064% | $13.93 | $49,072 | -26.95% | |
| 2024-05-21 | SIEGALL CLAY B | President and CEO | 20,434 0.0344% | $13.78 | $281,548 | -12.16% | ||
| 2024-05-21 | BIENAIME JEAN JACQUES | director | 2,000 0.0033% | $13.57 | $27,140 | -12.16% |
| Barchas Isaac | director | 2031181 2.3118% | $44.4M | 0 | 1 | |
| SIEGALL CLAY B | President and CEO | 665254 0.7572% | $14.54M | 10 | 0 | +7.54% |
| Tsai Philip | Chief Technical Officer | 43300 0.0493% | $946,538.00 | 3 | 0 | +5.1% |
| BIENAIME JEAN JACQUES | director | 36415 0.0414% | $796,031.90 | 5 | 0 | <0.0001% |
| WAGENHEIM PHILIP | director | 397397 0.4523% | $8.69M | 1 | 0 | <0.0001% |
| RAPP MICHAEL | director | 208742 0.2376% | $4.56M | 7 | 0 | <0.0001% |
| LAMATTINA JOHN L | director | 51828 0.059% | $1.13M | 1 | 0 | <0.0001% |
| Rosett Max | Chief Financial Officer | 47476 0.054% | $1.04M | 0 | 1 | |
| Turner Bruce | Chief Strategy Officer | 42300 0.0481% | $924,678.00 | 1 | 0 | +74.21% |
| Lefenfeld Michael | director | 26872 0.0306% | $587,421.92 | 3 | 0 | <0.0001% |
| Higgins Jack | Chief Scientific Officer | 16000 0.0182% | $349,760.00 | 0 | 1 | |
| Lechleider Robert | Chief Medical Officer | 15805 0.018% | $345,497.30 | 1 | 0 | +5.1% |
| Sarma Purnanand D | President and CEO | 10500 0.012% | $229,530.00 | 1 | 0 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.74B | |
$21,345,882 | 83 | 94.45% | $1.84B | |
$54,590,806 | 65 | 21.84% | $2.15B | |
$47,419,530 | 58 | 17.20% | $1.85B | |
$1,603,489 | 30 | 98.90% | $2.07B | |
$62,927,079 | 29 | 14.02% | $2.18B | |
$82,281,805 | 29 | -1.52% | $1.91B | |
Immunome, Inc. (IMNM) | $8,195,601 | 23 | -12.08% | $1.92B |
$169,638,586 | 22 | 30.82% | $1.72B | |
$18,854,717 | 21 | 22.51% | $1.97B | |
$103,194,328 | 13 | 9.02% | $2.2B | |
$18,336,420 | 12 | 24.03% | $1.92B | |
$2,859,892 | 10 | 29.21% | $2.13B | |
$94,976,497 | 10 | -10.72% | $2.19B | |
$93,268,646 | 8 | -37.22% | $1.85B | |
$4,623,072 | 7 | 11.07% | $2.21B | |
$7,605,533 | 5 | 17.10% | $1.88B | |
$3,200,000 | 5 | -11.36% | $1.91B | |
$666,380 | 5 | -16.60% | $2.15B |
| Increased Positions | 125 | +94.7% | 37M | +40.35% |
| Decreased Positions | 56 | -42.42% | 10M | -10.46% |
| New Positions | 50 | New | 7M | New |
| Sold Out Positions | 20 | Sold Out | 5M | Sold Out |
| Total Postitions | 201 | +52.27% | 118M | +29.89% |
| Fmr Llc | $271,841.00 | 11.87% | 13.06M | +7M | +111.7% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $175,266.00 | 7.65% | 8.42M | +142,906 | +1.73% | 2025-09-30 |
| Blackrock, Inc. | $121,229.00 | 5.29% | 5.82M | +52,044 | +0.9% | 2025-09-30 |
| Redmile Group, Llc | $104,587.00 | 4.57% | 5.02M | +151,160 | +3.1% | 2025-09-30 |
| Vanguard Group Inc | $101,885.00 | 4.45% | 4.89M | +368,674 | +8.15% | 2025-09-30 |
| Point72 Asset Management, L.P. | $100,446.00 | 4.39% | 4.82M | +138,701 | +2.96% | 2025-09-30 |
| Enavate Sciences Gp, Llc | $99,282.00 | 4.34% | 4.77M | 0 | 0% | 2025-09-30 |
| Ecor1 Capital, Llc | $84,933.00 | 3.71% | 4.08M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $77,924.00 | 3.4% | 3.74M | +760,690 | +25.51% | 2025-09-30 |
| Opaleye Management Inc. | $66,312.00 | 2.9% | 3.19M | -344,581 | -9.76% | 2025-09-30 |